clinical trial · NCT04152200
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1Primary HyperoxaluriaLumasiran
brief summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
started
Jan 21, 2020
primary completion
May 18, 2021
completion
Jun 23, 2025
last updated
Jul 18, 2025
official title
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol